{"id":"NCT01803646","sponsor":"Auris Medical, Inc.","briefTitle":"AM-101 in the Treatment of Acute Tinnitus 2","officialTitle":"Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2016-06","completion":"2016-06","firstPosted":"2013-03-04","resultsPosted":"2018-05-29","lastUpdate":"2018-05-29"},"enrollment":343,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tinnitus"],"interventions":[{"type":"DRUG","name":"AM-101","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AM-101 injection","type":"EXPERIMENTAL"},{"label":"Placebo injection","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this research study is to test the safety and effectiveness of the study drug, AM-101. AM-101 is tested for the treatment of tinnitus that started as the result of an injury to the inner ear or due to middle ear inflammation (otitis media). Subjects with tinnitus can take part in the study, if their tinnitus started within the last 3 months.","primaryOutcome":{"measure":"Efficacy: Change in Patient-reported Tinnitus Loudness Questionnaire (TLQ) Improvement From Baseline to Follow up Visit 3 (FUV3)","timeFrame":"Screening (D-14) versus final follow-up (D83)","effectByArm":[{"arm":"AM-101 0.87 mg/mL Gel","deltaMin":0.8,"sd":null},{"arm":"Placebo Gel","deltaMin":0.63,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.32"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["28608739"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":201},"commonTop":["Ear pain","Ear discomfort","Headache","Tinnitus","Hypoacusis"]}}